OpGen Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
10,134.80
5,671.50
17,352.10
19,166.80
15,419.30
13,368.10
Depreciation, Depletion & Amortization
661.80
573.90
624.70
656.00
669.10
730.90
Other Funds
877.30
180.70
3,714.80
1,069.80
1,038.60
982.40
Funds from Operations
8,595.70
4,916.80
13,141.80
17,440.90
13,711.70
11,654.80
Changes in Working Capital
1,107.90
468.70
1,136.20
190.30
592.20
580.80
Net Operating Cash Flow
7,487.80
5,385.50
14,278.00
17,250.60
14,303.90
11,074
Capital Expenditures
109.90
39.50
185.30
123.50
277.00
Sale of Fixed Assets & Businesses
-
-
1,367.20
-
-
Net Investing Cash Flow
109.90
39.50
1,181.90
123.50
277.00
Issuance/Reduction of Debt, Net
1,881.80
2,836.30
2,800.20
225.80
292.10
Net Financing Cash Flow
1,880.30
4,774.30
20,169.10
13,664.70
12,348.20
Net Change in Cash
5,717.40
650.80
7,064.70
3,696.90
2,270.20
Free Cash Flow
7,597.70
5,425.10
14,463.30
17,374.20
14,580.80
Deferred Taxes & Investment Tax Credit
-
-
129.10
-
-
-
Change in Capital Stock
1.50
1,937.90
17,368.90
13,890.50
12,640.30
Exchange Rate Effect
-
-
8.30
12.60
37.50

About OpGen

View Profile
Address
708 Quince Orchard Road
Gaithersburg Maryland 20878
United States
Employees -
Website http://www.opgen.com
Updated 07/08/2019
OpGen, Inc. operates as a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.